Academic Journal
Self-reported quality of life outcomes after Cenobamate initiation.
| Τίτλος: | Self-reported quality of life outcomes after Cenobamate initiation. |
|---|---|
| Συγγραφείς: | Toledo M; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Garcés-Pellejero M; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., López-Maza S; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Quintana M; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Bellido-Castillo E; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Casado-Cuadrado L; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Abraira L; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain. Electronic address: laura.abraira@vallhebron.cat., Santamarina E; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Campos-Fernández D; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain., Fonseca E; Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain. |
| Πηγή: | Epilepsy & behavior : E&B [Epilepsy Behav] 2026 Aug; Vol. 181, pp. 111090. Date of Electronic Publication: 2026 May 09. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Academic Press Country of Publication: United States NLM ID: 100892858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-5069 (Electronic) Linking ISSN: 15255050 NLM ISO Abbreviation: Epilepsy Behav Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Diego, CA : Academic Press, c2000- |
| Ιατρικοί όροι (MeSH): | Quality of Life*/psychology , Anticonvulsants*/therapeutic use , Anticonvulsants*/adverse effects , Chlorophenols*/therapeutic use , Chlorophenols*/adverse effects , Carbamates*/therapeutic use , Epilepsies, Partial*/drug therapy , Epilepsies, Partial*/psychology , Epilepsy*/drug therapy , Epilepsy*/psychology , Self Report*, Seizures/drug therapy ; Seizures/psychology ; Humans ; Female ; Male ; Adult ; Middle Aged ; Treatment Outcome ; Follow-Up Studies ; Prospective Studies ; Surveys and Questionnaires ; Depression ; Anxiety ; Young Adult ; Tetrazoles |
| Περίληψη: | Objective: Cenobamate (CNB) has demonstrated to be highly effective for the treatment of focal epilepsy. However, further real-world data beyond seizure control are needed. We aimed to assess the self-reported quality of life (QoL) in patients who initiated CNB considering efficacy, safety, cognitive and psychiatric outcomes. Methods: We prospectively recruited patients starting CNB in a tertiary center during 2 years. All patients had baseline and 6-month follow-up clinical visits, completing self-administered online questionnaires that included Hospital Anxiety and Depression Scale (HADS), Quality of life in Epilepsy Inventory-31 (QOLIE-31) and Short-Form-36 Health Survey (SF-36), as well as a Telephone-Montreal Cognitive Assessment (T-MoCA). Results: 106 subjects (91.5% focal epilepsy) were included, with a mean age 43 years and 6-months retention rate of 84.1%. Median monthly seizure frequency decreased from 3 (IQR 1-11) to 0.66 (IQR 0-4) at 6 months (p<0.001). Seizure freedom was achieved in 26.5%. Adverse events occurred in 51.9%, mainly somnolence and dizziness. Baseline anxiety and depressive symptoms were present in 55.4% and 41.4% of patients respectively, remaining unchanged in the follow-up. Cognitive function slightly improved (median T-MoCA 16 to 17, p=0.009), particularly in responders and seizure-free patients. QoL scores were below normative values at baseline. After adjusted multiple regression analysis, seizure frequency reduction was significantly associated with the SF-36 Mental Component (β=4.030; 95%CI: 1.277-6.783; p=0.005), particularly in the emotional role domain (β=4.976; 95%CI: 1.442-8.509; p=0.007). Conclusions: Greater seizure reduction in patients treated with CNB was associated with significant improvements in self-perceived QoL after 6 months. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M. Toledo declares research funding and speaker fees from UCB Pharma, GW Pharmaceuticals, Bial Pharmaceutical, Eisai Inc., Sanofi, Arvelle, and Esteve Laboratorios. S. Lopez-Maza declares travel suport from EISAI Inc. L. Abraira has received research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, Jazz Pharmaceuticals, EISAI Inc, Neuraxpharm, Exeltis, Angelini Pharma, Sanofi Genzyme and Esteve Laboratorios. D. Campos-Fernández has received travel support and research funding from UCB Pharma, Angelini Pharma and Jazz Pharmaceuticals. M. Quintana has received honoraria from UCB Pharma, Eisai Inc, Sanofi, GW Pharmaceuticals, Neuraxpharm Spain and Pierre Fabre Ibérica. E. Santamarina has received research funding and speaker fees from UCB Pharma, Bial Pharmaceutical, Eisai Inc. Arvelle, and Esteve Laboratorios. E. Fonseca declares research funding, speaker fees and travel support from UCB Pharma, Esteve laboratorios, Eisai Inc, Bial Pharmaceutical, Jazz Pharmaceuticals, Angelini Pharma and Sanofi Genzyme. None of the other authors has any conflict of interest to disclose. |
| Contributed Indexing: | Keywords: anxiety; cenobamate; cognition; depression; epilepsy; quality of life |
| Substance Nomenclature: | 0 (Anticonvulsants) P85X70RZWS (Cenobamate) 0 (Chlorophenols) 0 (Carbamates) 0 (Tetrazoles) |
| Entry Date(s): | Date Created: 20260510 Date Completed: 20260716 Latest Revision: 20260716 |
| Update Code: | 20260717 |
| DOI: | 10.1016/j.yebeh.2026.111090 |
| PMID: | 42107465 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1525-5069 |
|---|---|
| DOI: | 10.1016/j.yebeh.2026.111090 |